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Abstract
Background: Human serum albumin (HSA) is an abundant plasma protein that binds a wide
variety of hydrophobic ligands including fatty acids, bilirubin, thyroxine and hemin. Although HSA-
heme complexes do not bind oxygen reversibly, it may be possible to develop modified HSA
proteins or heme groups that will confer this ability on the complex.
Results: We present here the crystal structure of a ternary HSA-hemin-myristate complex,
formed at a 1:1:4 molar ratio, that contains a single hemin group bound to subdomain IB and
myristate bound at six sites. The complex displays a conformation that is intermediate between
defatted HSA and HSA-fatty acid complexes; this is likely to be due to low myristate occupancy in
the fatty acid binding sites that drive the conformational change. The hemin group is bound within
a narrow D-shaped hydrophobic cavity which usually accommodates fatty acid; the hemin
propionate groups are coordinated by a triad of basic residues at the pocket entrance. The iron
atom in the centre of the hemin is coordinated by Tyr161.
Conclusion: The structure of the HSA-hemin-myristate complex (PDB ID 1o9x) reveals the key
polar and hydrophobic interactions that determine the hemin-binding specificity of HSA. The
details of the hemin-binding environment of HSA provide a structural foundation for efforts to
modify the protein and/or the heme molecule in order to engineer complexes that have favourable
oxygen-binding properties.
Background
In the human body heme may be released into the circu-
lation during enucleation of erythrocytes or through
hemolytic injury. Free heme is immediately oxidized to
the ferric state, hemin, which is potentially toxic since it
may intercalate in lipid membranes and catalyze the for-
mation of hydroxyl radicals and the oxidation of low den-
sity lipoproteins [1]. This toxicity is largely averted though
the scavenging action of hemopexin, a protein that circu-
lates in plasma (~17 µM), binds hemin with extremely
high affinity (KD < 1 pM) and transports it to various tis-
sues – primarily liver cells – for intracellular catabolism
[2].
Human serum albumin (HSA), the most abundant
plasma protein (~640 µM) also has a high affinity for
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determined to be ~10 nM in a 3:5 (v/v) mix of dimethyl
sulfoxide and water [3] but the interaction is likely to be
even tighter in a more aqueous medium. HSA may pro-
vide a reserve binding capacity for situations when hemo-
pexin becomes saturated. The protein is principally
characterized by its remarkable ability to bind a broad
range of hydrophobic small molecule ligands including
fatty acids, bilirubin, thyroxine, bile acids and steroids; it
serves as a solubilizer and transporter for these com-
pounds and, in some cases, provides important buffering
of the free concentration [4]. HSA also binds a wide vari-
ety of drugs in two primary sites [5,6] which overlap with
the binding locations of endogenous ligands. The protein
is a helical monomer of 66 kD containing three homolo-
gous domains (I-III) each of which is composed of A and
B subdomains [5]. Despite the internal structural symme-
try, the three domains have different capacities for bind-
ing fatty acids [7–10], thyroxine [11] and drugs
[5,8,12,13]. Binding studies indicate a single site for
hemin in subdomain IB [14] which corresponds to a
binding site for fatty acids [8–10].
The ability of HSA to bind hemin has stimulated efforts to
develop HSA-heme complexes that mimic the reversible
oxygen-binding properties of heme proteins such as
myoglobin and hemoglobin. One difficulty with this
approach is that even if HSA-bound hemin is reduced to
heme, stable and reversible oxygen binding by the com-
plex cannot be observed (reviewed in [15,16]), because
the heme binding site does not provide a molecular envi-
ronment sufficiently similar to that found in myoglobin
or hemoglobin. However, recent work has shown that
artificial heme derivatives associate with HSA and provide
significant oxygen-binding capacity [15,17–21]. Although
such compounds have extensive modifications to the por-
phyrin ring and are not expected to bind to the protein in
the same fashion as heme, they represent a promising line
of inquiry for the development of artificial blood
substitutes.
In order to advance our understanding of the heme-bind-
ing properties of HSA and the development of viable
blood substitutes based on HSA-heme complexes, we
have solved the crystal structure of a HSA-hemin-myr-
istate complex. The structure reveals a previously undetec-
ted conformational state of the protein and provides a
detailed view of the heme binding site. Our results are
compared with a recently reported structure for methe-
malbumin [22].
Results and Discussion
Overall structure of the complex
The complex of HSA with hemin and myristate was pre-
pared using a HSA:hemin:myristate mole ratio of 1:1:4
(Materials and Methods). The crystal structure was solved
by molecular replacement and refined to a resolution of
3.2 Å. The refined model has an Rfree value of 28.8% and
good stereochemistry (Table 1). It contains a single mole-
cule of hemin bound to the hydrophobic cavity in sub-
domain IB and myristates bound at six sites on the protein
(Figure 1a). These correspond to fatty acid sites 2–7 which
were identified in our previous work [8,9]. Fatty acid site
1 is occupied by hemin under our experimental condi-
tions and prevents fatty acid binding by steric exclusion.
The electron density clearly indicates the binding configu-
ration of the porphyrin ring and the two propionate
groups of the bound hemin (Figure 1b), though it is pos-
sible that the molecule binds in two overlapping orienta-
tions that are related by a two-fold rotation (180°) about
its centre. In either of the two orientations the propionate
groups appear to be able to make the same interactions
with the protein (to residues R114, H146 and K190) but
the asymmetric location of the vinyl groups projecting
from the hydrophobic end of the hemin molecule would
occupy different positions. From the structure it appears
that both configurations of the vinyl group could be
accommodated within the binding pocket but may result
in small adjustments of sidechains lining the pocket and
of the exact position of the porphryin ring and its iron
centre. Even at higher resolution, this ambiguity is not
resolved [22] and it may therefore reflect a genuine degen-
eracy in hemin binding.
The density for the fatty acids is generally rather weak,
indicating partial occupancy as would be expected given
the 4:1 mole ratio of fatty acid to HSA used to prepare the
complex. Although there is usually clear density to indi-
cate the position of the fatty acid carboxylate moiety in
each binding pocket, the density for the methyl end of the
methylene tail is weak or absent. As a result, only the vis-
ible portion of the fatty acid tails has been included in the
refined model.
Conformational changes
A surprising finding is that the HSA-hemin-myristate
complex adopts a conformation that is intermediate
between the structure of unliganded HSA [5,12,23] and
that observed previously for HSA-fatty acid complexes [8–
10]. The structural changes associated with fatty acid bind-
ing in previous work can be regarded essentially as rigid-
body rotations of domains I and III relative to II that pivot
around the mid-point of the long inter-domain helices
(Figures 2a and 2b) and are driven primarily by binding
of fatty acids to the I-II and II-III interfaces, though con-
tacts between domains I and III may also be involved
[8,24]. This conformational change appears to be inde-
pendent of the length or degree of unsaturation of the
fatty acid methylene tail [9,10] though it must be borne inPage 2 of 9
(page number not for citation purposes)
BMC Structural Biology 2003, 3 http://www.biomedcentral.com/1472-6807/3/6mind that in these studies HSA-fatty acid complexes were
prepared for crystallisation using a large molar excess of
fatty acid to protein (>10:1) [9,10]. For the present inves-
tigation a 1:1 HSA-hemin complex was incubated with 4
moles of myristate per mole of HSA and then concen-
trated in a single step prior to crystallisation (see Materials
and Methods). The crystals obtained belong to space-
group P21212, which has not previously been observed for
HSA and was an early indication of the potential novelty
of the conformational state. As observed for HSA-fatty
acid complexes, the conformation of the HSA-hemin-
myristate complex comprises changes from the unlig-
anded state involving rigid-body rotations of domains I
and III with respect to domain II; however in this case the
particular rotation of domain I relative to domain II is
only about 85% complete when compared to that
observed in other HSA-fatty acid complex structures (Fig-
ures 2a and 2b). The difference in the orientation of
domain III relative to domain II in the HSA-hemin-myr-
istate and other HSA-fatty acid complexes [8–10,24] is
rather small and may be due to differences in crystal
packing.
It is conceivable that the difference in the orientation of
domain I relative to domain II in the HSA-hemin-myr-
istate and other HSA-fatty acid complexes is also due to
changes in the crystal-packing environment between the
two crystal forms (P21212 and C2). However, considera-
tion of the structure suggests that it is more likely to be
due to differences in the level of bound fatty acid (Figures
2c and 2d). The crystal structure of the HSA-myristate
complex – prepared using a high myristate:HSA mole
ratio – showed evidence for two fatty acid molecules
bound in a tail-to-tail configuration in the contiguous
fatty acid sites 2 and 2' which straddle the interface
between domains I and II. Occupancy of site 2 is believed
to be primarily responsible for driving the conformational
change between these two domains (Figure 2d). In the
HSA-hemin-myristate complex, there is no evidence for
fatty acid binding to site 2' and indeed the density for the
fatty acid bound to site 2 is relatively weak, probably as a
Crystal structure of the HSA-myristate-hemin complexFigure 1
Crystal structure of the HSA-myristate-hemin complex (a) The protein secondary structure is shown schematically 
with the sub-domains colour-coded as follows: IA, red; IB – light red; IIA, green; IIB – light-green; IIIA, blue; IIIB – light blue; this 
colour scheme is maintained throughout. Ligands are shown in a space-filling representation, coloured by atom type: carbon – 
grey; nitrogen – blue; oxygen – red; iron – orange. Fatty acid binding sites are labelled 2–7. Except where stated otherwise, 
molecular graphics were prepared using Bobscript [32] and Raster3D [33]. (b) An Fobs-Fcalc simulated annealing omit map [30] 
contoured at 2.5σ for hemin bound to subdomain IB. Selected amino acid sidechains are shown coloured by atom type. The 
dashed line indicates the two-fold symmetry axis that may relate alternative binding configurations of the porphyrin ring. The 
helix which overlies the bound hemin (residues 174–196) has been rendered semi-transparent.Page 3 of 9
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be that binding to site 2' is required to drive the more
extensive conformational change between domains I and
II. Although fatty acids longer than C14 are not observed
to occupy site 2', they nevertheless appear to drive the
"full" conformational change; this is most likely because
the methylene tail of a long-chain fatty acid bound to site
2 begins to occupy site 2' [9,10] and may therefore play
the same structural role as the binding of a second mole-
cule of a shorter-chain fatty acid to site 2'. An independent
crystallographic study on hemin binding to HSA in the
presence of myristate reportedly obtained a conformation
very similar to that found for HSA-myristate at very high
myristate:HSA mole ratios [8], but the amount of myr-
istate used was not given and the coordinates are not yet
available to allow a direct comparison with our present
structure [22]. Whatever the precise mechanism underly-
ing the fatty-acid induced conformational changes, there
is no evidence to suggest a connection between binding of
hemin and the new conformational stage identified in the
present work. Moreover, it is likely that the hemin-bind-
ing site itself is not affected by fatty acid induced confor-
mational changes.
Details of the hemin binding site
Hemin binds to a hydrophobic, D-shaped cavity in sub-
domain IB. The hydrophobic porphyrin ring is essentially
buried in the core of the subdomain with the propionate
groups located at the wide entrance to the pocket where
they can interact with solvent and several basic amino acid
sidechains (see below). In the absence of ligand this cavity
is partially occluded by two tyrosine residues (138 and
161) which stack on top of one another [24]. Upon hemin
binding both sidechains undergo χ1 rotations of around
90° thereby opening up the binding pocket and helping
to clamp the ligand in place. Very similar rotations of
these sidechains were observed with fatty acid binding [9];
indeed there is complete overlap between the positions of
fatty acid and hemin when bound in this site. Other
sidechains, including Leu139, His146, Ile142 and
Leu154, exhibit modest adjustments upon heme binding.
There is a slight expansion of subdomain IB upon binding
of hemin: the separation of helices 8 and 10 on either side
of the ligand increases by about 1.4 Å. A similar sized
expansion was also observed for fatty acid binding to this
pocket [8]. The expansion may be constrained by the
disulfide bridge between Cys124 and Cys169 that links
helices 7 and 9 respectively (Figure 3a).
All of the structural components of subdomain IB, includ-
ing the polypeptide linker connecting it to subdomain IA
and helices 7–10, contribute to the hemin binding site.
The hemin group binds with its plane oriented at about
30° to the directional axes of helices 8–10; this orienta-
tion is determined by the packing of the hemin group
against the residues lining the interior wall of the pocket.
With the exception of Tyr138 and Tyr161, these are
entirely hydrophobic sidechains. The hydroxyl group of
Tyr138 is relocated to the exterior of the domain where it
interacts with solvent, but the hydroxyl group of Tyr161
makes a direct interaction with the central Fe3+ atom, pro-
viding a fifth point of coordination (Figure 3b). The
entrance to the pocket, which is rather open, faces towards
the interdomain cleft and contains three basic residues
that coordinate the two propionate groups on hemin.
Lys190 adopts a central position and makes salt-bridges to
both propionate groups (2.7 and 3.0 Å); His146 provides
a second electrostatic interaction with one heme carboxy-
late (3.0 Å) while the guanidinium group of Arg114 inter-
acts with the other (2.8 Å). Arg117, which lies towards the
top end of the pocket entrance and invariably interacts
with fatty acids which bind at this site [9], is not involved
in coordinating the propionate groups of the hemin. The
electrostatic interactions to the propionate groups are
clearly important for hemin binding; the number of resi-
dues involved in coordinating the propionate groups is
fewer that the seven observed in hemopexin [25] but
more than the one or two basic residues found to fill this
Table 1: Data collection and refinement statistics
DATA COLLECTION
a (Å) 80.08
b (Å) 202.70
c (Å) 39.37
Resolution range (Å) 27.2–3.2
Independent reflections 10,825
Multiplicity1 2.7(2.6)
Completeness (%) 96.2(92.4)
I/σ 8.1(2.1)
Rmerge(%)2 5.7(34.5)
MODEL REFINEMENT
Nonhydrogen atoms 4479
Rmodel (%)3 28.8
Rfree (%)4 23.1
r.m.s deviation from ideal bond lengths 
(Å)
0.007
r.m.s deviation from ideal angles (°) 1.4
Average B-factor (Å2) 75.3
PBD ID 1o9x
1Values for the outermost resolution shell are given in parentheses. 2 
Rmerge = 100 × ∑h∑j|Ihj - Ih|/∑h∑jIhj where Ih is the weighted mean inten-
sity of the symmetry related reflections Ihj 3 Rmodel = 100 × ∑hkl|Fobs - 
Fcalc|/∑hklFobs where Ih where Fobs and Fcalc are the observed and calcu-
lated structure factors respectively. 4Rfree is the Rmodel calculated using a 
randomly selected 5% sample of reflection data omitted from the 
refinement.Page 4 of 9
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Conformational changes associated with variations in fatty acid content (a) Superposition of HSA-hemin-myristate 
(opaque) on defatted HSA (semi-transparent). (b) Superposition of HSA-hemin-myristate (opaque) on HSA-myristate (semi-
transparent). HSA-hemin-myristate was prepared with a 4-fold molar excess of fatty acid whereas the HSA-myristate complex 
was prepared with a 12-fold molar excess [9] which saturates the binding sites. The colour scheme is the same as Figure 1. In 
each case the structures were superposed using the Cα atoms from domain II (residues 197–383). Arrows indicate the relative 
domain movements. (c) Close-up views of myristate binding site 2 which traverses the interface between domains I and II for 
HSA-hemin-myristate. Selected amino acid sidechains are shown coloured by atom type. The fatty acid is depicted in a space 
filling-representation. Only the first seven carbon atoms of the methylene tail for which there is clear electron density are 
shown; the remainder of the tail is disordered but presumable extends further upward. (d) A similar close-up view of the same 
site in the HSA-myristate structure [9]. In this case the site is occupied by two fatty acid molecules in a tail-to-tail configura-
tion. The upper part of fatty acid site 2 is labelled 2'. The additional relative movement of the two domains at the higher fatty 
acid concentration is evident from the relative dispositions of R10 and D255, which interact across the top of the bound fatty 
acid.Page 5 of 9
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Detailed structure of the hemin-binding site in HSA and comparison with myoglobin (a) Side-view of subdomain 
IB of HSA indicating the comparative binding configurations of hemin (grey carbon atoms) and myristate (yellow carbon 
atoms). Helices 8–10 are labelled h8-h10. The structures of HSA-hemin-myristate and HSA-myristate [9] were superposed 
using the Cα atoms of subdomain IB (residues 107–196). The myristate lies along the upper hydrophobic surface of the D-
shaped cavity that accommodates hemin. Note that R117, which serves to coordinate the carboxylate group of myristate, is 
not involved in this function for hemin. (b) Close-up view of the hemin-binding pocket in subdomain IB. The propionate groups 
of hemin are co-ordinated by R114, H146 and K190. (c) Close-up view of the heme-binding pocket of sperm-whale myoglobin 
(PDB ID: 4 mbn). Electrostatic interactions between protein side-chains and hemin are indicated by dashed cyan lines. This fig-
ure was prepared using Molscript [34] and Pymol [35].Page 6 of 9
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opposite end of the pocket there is a small opening which
is large enough to admit solvent molecules.
In terms of the general hydrophobicity of the pocket and
the coordination of the propionate groups by basic resi-
dues, HSA appears to have similar features to the heme
binding site on myoglobin or hemoglobin. However,
although both proteins are helical there is little similarity
in the architectures of their heme binding pockets. In par-
ticular, HSA lacks the pair of histidine residues that serve
to enhance and regulate the relative oxygen- and carbon
monoxide-binding properties of myoglobin and hemo-
globin. Modification of the heme-binding pocket on HSA
or of the heme-group itself is likely to be required to
achieve a protein-heme complex capable of reversible
oxygen binding. Although various heme derivatives have
been produced that exhibit reversible oxygen binding in
association with HSA [19–21,26], these contain sizeable
additions to the porphyrin ring structure and are unlikely
to bind to subdomain IB on HSA in the same configura-
tion that has been observed for hemin. Nevertheless, the
detailed architecture of the heme-binding pocket as
revealed by this crystallographic study will facilitate the
design of new heme derivatives that will be better accom-
modated in this site and may therefore bind with higher
affinity. It will also enable the design of mutagenesis
experiments to tailor the pocket to bind modified hemes.
Conclusions
The structure of the HSA-hemin-myristate complex
reported here reveals a new conformational state of the
protein, one that is intermediate between unliganded
HSA and the saturated HSA-fatty acid complex. The obser-
vation of this conformation is likely due to the use of sub-
saturating amounts of fatty acid in preparing the crystals
and provides new insights into the mechanism of confor-
mational change.
The single hemin-binding pocket in subdomain IB of HSA
consists of a deep hydrophobic slot that provides three
basic residues at its entrance to coordinate the two propi-
onate groups of the hemin. This provides a framework for
future attempts to engineer the protein and heme deriva-
tive in order to generate high-affinity HSA-heme com-
plexes which bind oxygen reversibly and may serve as
effective artificial blood substitutes.
Methods
Preparation and crystallization of the HSA-hemin-
myristate complex
Recombinant HSA (Recombin®), kindly provided by
Delta Biotechnology (Nottingham, UK), was defatted and
purified by gel filtration to be dimer-free in 50 mM potas-
sium phosphate, 50 mM NaCl, pH 7.0 to a concentration
of 110 mg/ml (1.67 mM) essentially as described previ-
ously [12]. Immediately prior to use hemin was dissolved
at 10 mM in dimethylsulfoxide (DMSO) in a foil-wrapped
microcentrifuge tube. The hemin and HSA solutions were
mixed to give a hemin:HSA molar ratio of 1.1 to 1.0, and
incubated with rotation in the dark at room temperature
for at least 12 hours. The resulting complex was then con-
centrated using a 10 kDa molecular weight cut-off ultrafil-
tration device (Vivaspin, Millipore), and washed in
repeated cycles of concentration and dilution with 50 mM
potassium phosphate buffer, pH 7.0 to reduce the final
concentration of DMSO < 0.1% (v/v). Myristic acid was
freshly dispersed with the aid of mild heating in 20 mM
potassium phosphate pH 7.0 to obtain a suspension with
a concentration of 2.5 mM. The HSA-hemin complex was
incubated with myristic acid, at a fatty acid:HSA molar
ratio of 4:1, by rotation at room temperature for one hour.
The complex was then concentrated – in a single step – in
a Vivaspin ultrafiltration device and analysed on a poly-
acrylamide gel to estimate the protein concentration.
Crystals were grown by sitting-drop vapour diffusion at
4°C using methods similar to those described previously
[8,9,27]. Crystallization screens were set up at a protein
concentration of >90 mg/ml using 20 to 40% PEG 3350
(Sigma-Aldrich) in 50 mM potassium phosphate buffer,
pH 7.0 as the precipitant; the sitting drop initially con-
tained 3.5 µl of the protein solution and 3.5 µl of the res-
ervoir mixture. Three days after streak-seeding, crystals
were observed at 24, 26, 28 and 30% PEG; the largest crys-
tals were observed at 24 and 26 % PEG.
Data collection, processing, structure determination and 
refinement
X-ray diffraction data were collected at Daresbury SRS
(station 9.6) and EMBL/DESY Hamburg (beamline X11)
using crystals mounted in sealed glass capillaries main-
tained at room temperature. The data were indexed and
measured with MOSFLM and scaled with SCALA [28]. The
crystals belong to space-group P21212. Efforts to solve the
phase problem by molecular replacement with AMoRe
[29] produced a promising solution for domain II of the
protein (residues 197–383) taken from the HSA-myristate
structure (PDB ID 1e7g) [9]; however, orientations for
domains I and III were not found. Since the solution for
domain II appeared to yield a sensible packing arrange-
ment for HSA molecules in the unit cell, it was used as a
starting point for rigid-body refinement using CNS [30].
The HSA-myristate model (1e7g) was initially refined as a
single rigid body using data from 10–30 Å; thereafter, the
protein was split into three domains (5–196, 197–383,
384–584) which were allowed to move independently
and rigid body refinement was applied as the high resolu-
tion limit of the incorporated data was extended in 1 Å
steps from 10 Å to 4 Å and finally to 3.2 Å. During thisPage 7 of 9
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to 34.5%. An electron density map calculated at this stage
showed clear electron density for the whole protein and
the ligand molecules. Manual building in O [31] was
interspersed with rounds of positional and group temper-
ature factor refinement. Data collection and refinement
statistics are summarized in Table 1.
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